AgomAb Therapeutics NV ADR (AGMB) Financial Statements

9 Followers

AgomAb Therapeutics NV ADR Financial Overview

AgomAb Therapeutics NV ADR's market cap is currently $651.06M. The company's EPS TTM is $; its P/E ratio is -31.73; AgomAb Therapeutics NV ADR is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 26
Income Statement
Total Revenue	€ 0.00
Gross Profit	€ -210.36K
Operating Income	€ -59.27M
EBITDA	€ -62.27M
Net Income	€ -60.08M
Balance Sheet
Cash & Short-Term Investments	€ 116.51M
Total Assets	€ 153.71M
Total Debt	€ 1.25M
Net Debt	€ -85.16M
Total Liabilities	€ 22.80M
Stockholders' Equity	€ 130.90M
Cash Flow
Free Cash Flow	€ -51.74M
Operating Cash Flow	€ -51.74M
Investing Cash Flow	€ -33.00M
Financing Cash Flow	€ -338.00K

Currency in EUR

AgomAb Therapeutics NV ADR Earnings and Revenue History

Income Statement >

AgomAb Therapeutics NV ADR Debt to Assets

Balance Sheet >

AgomAb Therapeutics NV ADR Cash Flow

Cash Flow >

AgomAb Therapeutics NV ADR Forecast EPS vs Actual EPS

Earnings >